로딩 중…
StockDiggingStockDigging

Humedix

200670· KOSDAQ
₩26,850-2.36%
2026-06-19

Price Chart

Humedix-54.95%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap301.52B KRW
Revenue170.43B KRW
Net Income51.35B KRW
Total Assets338.44B KRW
Net Assets310.60B KRW
Employees371
Value
P/E5.87x
P/B0.97x
P/S1.77x
EV/EBITDA6.32x
FCF Yield12.34%
Profitability
ROE16.53%
ROA15.17%
Op. Margin23.36%
Revenue Growth0.95%
Earnings Growth-3.23%
Financial Health
Debt Ratio108.96%
Total Debt0 KRW
FCF37.21B KRW
Cash50.10B KRW
Current Ratio8.03x
Net Debt/EBITDA-1.26x
Dividend
Div. Yield3.35%
Div. Growth46.03%
Performance
1Y Return-54.95%
1M Return-6.45%
From 52W High-65.22%
1Y MDD-67.81%
Trading
Volume55,695 shares
Foreign Own.8.21%
Per Share
EPS4,573 KRW
BPS27,986 KRW

Company Info

CEO 강민종
Employees 371
Founded 2003
HQ 경기도 성남시, KR

Humedix, established in 2003 for the manufacturing and sale of functional foods, changed its name from its original in 2010 and was listed on KOSDAQ in 2014. Through research and development of hyaluronic acid and PDRN, the company produces and supplies fillers, botulinum toxin, arthritis therapeutics, and cosmetics to domestic and international healthcare markets. Humedix strengthens its market presence by acquiring European CE and Chinese NMPA certifications for its proprietary HI method fillers. It maximizes synergy through heparin sodium localization and an aesthetic solution portfolio, and is headquartered in Seongnam-si, Gyeonggi-do.